Jose Rubio

Jose Rubio

Auto-generated profile, based on publicly available information

Jose Rubio

Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Science Advances
Verified
Journal Article
Open access
PCPing-Min Chen
Ping-Min Chen
EKEri Katsuyama
Eri Katsuyama
ASAbhigyan Satyam
Abhigyan Satyam
HLHao Li
Hao Li
JRJose Rubio
Jose Rubio
GTGeorge Tsokos
George Tsokos
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD + , is up-regulated in CD8 + T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8 + T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8 + T cell–targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.

27 May 2012 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
DVDanica Maria Vodopivec
Danica Maria Vodopivec
JRJose Enrique Rubio
Jose Enrique Rubio
AFAlessia Fornoni
Alessia Fornoni
OLOliver Lenz
Oliver Lenz
Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms from these citations in MEDLINE to find additional publications. We relied on a literature review published in 2003 by Baeksgaard et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to present day. All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

9 March 2025 in Clinical Immunology
Verified
Journal Article
Closed access
CLChangming Lu
Changming Lu
SLShanrun Liu
Shanrun Liu
MGMin Gao
Min Gao
JRJose Rubio
Jose Rubio
WCW. Winn Chatham
W. Winn Chatham
John D. MountzJohn D. Mountz
John D. Mountz

31 August 2021 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
JRJose Rubio
Jose Rubio
VKVasileios Kyttaris
Vasileios Kyttaris
Objective: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis (LN), improved complete renal response rates in patients with LN in a phase 2 trial. This study aimed to evaluate the efficacy and safety of voclosporin for the treatment of LN.Methods: This multicenter, double‐blind, randomized phase 3 trial was done in 142 hospitals and clinics across 27 countries. Patients with a diagnosis of systemic lupus erythematosus and LN, according to the American College of Rheumatology criteria, who had undergone a kidney biopsy within 2 years that showed class III, IV, or V (alone or in combination with class III or IV) were eligible for this study. Patients were randomly assigned (1:1) to receive oral voclosporin (23.7 mg twice daily) or a placebo, on a background of mycophenolate mofetil (1 g twice daily) and rapidly tapered low‐dose oral steroids, by use of an interactive web response system. The primary endpoint was complete renal response at 52 weeks, defined as a composite of urine protein creatinine ratio of 0.5 mg/mg or less, stable renal function (defined as estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73m2 or no confirmed decrease from baseline in eGFR of > 20%), no administration of rescue medication, and no more than 10 mg prednisone equivalent per day for 3 or more consecutive days or 7 or more days during Week 44 through Week 52 (just before the primary endpoint assessment). Safety was also assessed. Efficacy analysis was by intention to treat, and safety analysis was by randomized patients receiving at least one dose of study treatment.Results: Between April 13, 2017, and October 10, 2019, 179 patients were assigned to the voclosporin group and 178 were assigned to the placebo group. The primary endpoint of complete renal response at Week 52 was achieved in significantly more patients in the voclosporin group than in the placebo group (73 [41%] of 179 patients vs 40 [23%] of 178 patients; odds ratio, 2.65; 95% confidence interval [CI] 1.64‐4.27; P < 0·0001). The adverse event profile was balanced between the two groups; serious adverse events occurred in 37 (21%) of 178 patients in the voclosporin group and 38 (21%) of 178 patients in the placebo group. The most frequent serious adverse event involving infection was pneumonia, occurring in seven (4%) patients in the voclosporin group and in eight (4%) patients in the placebo group. A total of six patients died during the study or study follow‐up period (one [<1%] patient in the voclosporin group and five [3%] patients in the placebo group). None of the events leading to death were considered by the investigators to be related to the study treatments.Conclusion: Voclosporin in combination with mycophenolate mofetil (MMF) and low‐dose steroids led to a clinically and statistically superior complete renal response rate versus MMF and low‐dose steroids alone, with a comparable safety profile. This finding is an important advancement in the treatment of patients with active LN.

3 September 2019 in European Journal of Rheumatology
Verified
Journal Article
Open access
JGJoyce Goggins
Joyce Goggins
APAnne Plunkett
Anne Plunkett
DMDevyani Misra
Devyani Misra
JRJose E. Rubio
Jose E. Rubio
CSCarla Scanzello
Carla Scanzello
MAMatt B. Au
Matt B. Au
Cite this article as: Rubio JE, Scanzello C, Felson DT, Au MB, Goggins J, Plunkett A, et al. Correlation between senescence-associated secretory phenotypes factors in synovial fluid and serum and structural changes in osteoarthritis. Eur J Rheumatol 2020; 7(1): 44-5.